AORT
Artivion, Inc.
AORT lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AORT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Weak |
AORT's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AORT PE Valuation
AORT has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AORT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
AORT has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AORT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.05 | — |
| Q3 2026 | -$0.35 | -$0.10 |
| Q2 2026 | -$0.06 | +$0.37 |
| Q1 2026 | $0.25 | +$0.76 |
| Q4 2025 | $0.21 | +$0.53 |
| Q3 2025 | -$0.25 | -$0.23 |
| Q2 2025 | -$0.43 | -$0.22 |
| Q1 2025 | -$0.51 | -$0.27 |
| Q4 2024 | -$0.32 | +$0.43 |
AORT is still losing money, but far less than before: $0.35 per share over the past year, against $1.03 at its worst in late 2022.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AORT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $123.8M | +9.2% |
| Q2 2026 | $125.8M | +11% |
| Q1 2026 | $116.3M | +18% |
| Q4 2025 | $116M | +19% |
| Q3 2025 | $113.4M | +18% |
| Q2 2025 | $113M | +15% |
| Q1 2025 | $99M | +1.6% |
| Q4 2024 | $97.3M | +3.9% |
AORT's revenue has grown year over year for 23 quarters in a row: $124M last quarter, up 9.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.4% | -8.7 points |
| Q2 2026 | -6.7% | -14 points |
| Q1 2026 | 5% | +2.8 points |
| Q4 2025 | 9.2% | +6.5 points |
| Q3 2025 | 11% | +6.5 points |
| Q2 2025 | 7.4% | +0.8 points |
| Q1 2025 | 2.2% | -24 points |
| Q4 2024 | 2.7% | -0.6 points |
AORT has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AORT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AORT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.6M | -200% |
| Q2 2026 | -$12M | -202% |
| Q1 2026 | -$6.8M | +$13.7M |
| Q4 2025 | -$7.9M | -191% |
| Q3 2025 | $17.7M | +126% |
| Q2 2025 | $11.7M | +224% |
| Q1 2025 | -$20.6M | -$11.5M |
| Q4 2024 | $8.7M | -2.2% |
AORT's free cash flow was −$44M over the past year, against $18M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AORT on cash generation, producing positive trailing cash flow while its opponent burns cash.
AORT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +177K shares |
| 1 year | -0.1% | -57K shares |
| 3 years | +19% | +7.8M shares |
| 5 years | +9.6% | +4.3M shares |
| Available history | +29% | +10.9M shares |
AORT has 49M diluted shares, about the same as a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AORT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AORT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.5x | High |
| Q2 2026 | 6.3x | High |
| Q1 2026 | 2.6x | Moderate |
| Q4 2025 | 2.7x | Moderate |
| Q3 2025 | 2.9x | Moderate |
| Q2 2025 | 4.0x | Elevated |
| Q1 2025 | 7.0x | High |
| Q4 2024 | 4.1x | High |
AORT's net debt is about 8.5 years of its operating earnings (EBITDA), up from 2.9 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AORT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.0 | Neutral |
| Stochastic | 10.1 | Oversold |
AORT's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AORT PE vs Healthcare Sector
| Metric | AORT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AORT has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AORT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.7 | 11% below |
| 20 week MA | $24.2 | 20% below |
| 50 week MA | $30.8 | 37% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $25.7 | 24% below |
AORT is in a downtrend: it's below all five of its weekly moving averages, and 24% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AORT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.7 | $23.5 | -12% |
| 2021 | $23.5 | $20.4 | -14% |
| 2022 | $20.4 | $11.8 | -42% |
| 2023 | $11.8 | $17.9 | +51% |
| 2024 | $17.9 | $29.0 | +62% |
| 2025 | $29.0 | $46.3 | +60% |
| 2026 YTD | $46.3 | $19.4 | -58% |
AORT has finished lower in three of the last six years. It's down 58% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over AORT on returns for 2026, with the stronger performance.